News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Elan Corporation PLC 2Q Loss Narrows As MS Drug Sales Grow
July 21, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AP -- Losses are narrowing at Elan Corp. PLC as sales of its key drug, the multiple sclerosis-fighting Tysabri, keep growing in the United States and Europe, the Irish biopharmaceutical company reported Tuesday.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
IPO tracker
Generate Clocks Largest IPO Since 2024 With $400M Raise
February 27, 2026
·
5 min read
·
Tristan Manalac
Special edition
Deep Dive: BioSpace Takes On JPM26 in San Francisco
February 27, 2026
·
2 min read
·
Annalee Armstrong
Deals
Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+
February 26, 2026
·
1 min read
·
Tristan Manalac
C-suite
Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home
February 25, 2026
·
2 min read
·
Annalee Armstrong